Lead Product(s) : VVN461
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VivaVision Finds Positive Phase 2 Results for VVN461 in Post-Cataract Inflammation
Details : VVN461 is a potent non-steroidal dual JAK1/TYK2 immunomodulator, being investigated for the treatment of post-operative inflammation following cataract surgery.
Product Name : VVN461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : VVN461
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD
Details : LP-003 is a novel humanized monoclonal anti-IgE antibody candidate, which is being evaluated for the treatment of patients with chronic spontaneous urticaria.
Product Name : LP-003
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Picankibart
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent’s Phase 2 Study of Picankibart in Ulcerative Colitis Meets Primary Endpoint
Details : IBI112 (picankibart) an antibody, specifically binds to IL-23p19 inhibiting IL-23 receptor-mediated signaling pathway. It is being investigated in patients with moderate to severe ulcerative colitis.
Product Name : IBI112
Product Type : Antibody
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Picankibart
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Picankibart
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent’s Phase 2 Study of Picankibart in Ulcerative Colitis Meets Primary Endpoint
Details : IBI112 (picankibart) is a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection. It is being evaluated in chinese subjects with moderately to severely active ulcerative colitis.
Product Name : IBI112
Product Type : Antibody
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Picankibart
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Qiming Venture Partners
Deal Size : $1.4 million
Deal Type : Series B Financing
LongBio Announced the Completion of Series B2 Financing, Led by Qiming Venture Partners
Details : The financing aims to advance the clinical development of the company's lead product LP-003, a best-in-class, anti-IgE antibody, which is being evaluated for Chronic Spontaneous Urticaria.
Product Name : LP-003
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Qiming Venture Partners
Deal Size : $1.4 million
Deal Type : Series B Financing
Lead Product(s) : VVN461
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VivaVision Ph 2 of VVN461 Shows Positive Results for Post-Cataract Surgery Inflammation
Details : VVN461 is a potent non-steroidal dual JAK1/TYK2 immunomodulator, which is currently being evaluated for the treatment of post-operative inflammation following cataract surgery.
Product Name : VVN461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2024
Lead Product(s) : VVN461
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
Details : LP-003 is a novel monoclonal anti-IgE antibody, which is currently being evaluated for the treatment of adults with moderate-to-severe chronic spontaneous urticaria.
Product Name : LP-003
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 25, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZH901
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
Zephyrm Seeks Hong Kong IPO to Fund Phase 3 Cell Therapy Trials
Details : The proceeds will be used to support phase 3 trials of ZH901, a cell therapy in a lung condition and graft-versus-host disease (GvHD).
Product Name : ZH901
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : ZH901
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : LNK01001
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : China Grand Prosperity Investment
Deal Size : $44.0 million
Deal Type : Series C Financing
Details : The proceeds will be used for the development of second-generation highly selective and third-generation tissue-specific JAK inhibitors, including LNK01001, while also exploring the potential of innovative target-based drug development.
Product Name : LNK01001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : LNK01001
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : China Grand Prosperity Investment
Deal Size : $44.0 million
Deal Type : Series C Financing
Lead Product(s) : LNK01001
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LNK01001 is a JAK1 selective inhibitor which is being investigated in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerant to conventional synthetic disease-modifying anti-rheumatic drugs.
Product Name : LNK01001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2023
Lead Product(s) : LNK01001
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable